We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Infectious Diseases

Single-dose Cervarix induces durable seropositivity but fails HPV‑16 GMC non-inferiority versus three-dose Gardasil-4: implications from the PRIMAVERA immunobridging trial

MedXY Editorial Team•Nov 24, 2025•Infectious Diseases
HPV vaccineimmunobridgingsingle-dose

Title

Single-dose bivalent HPV vaccine (Cervarix) yields high seropositivity but fails non-inferiority for HPV-16 antibody concentrations versus three-dose quadrivalent regimen

Highlights

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Nine-Valent HPV Vaccine Cuts Cancer Risk Nearly in Half for Males: Landmark Study Supports Sex-Neutral ImmunizationA large-scale retrospective cohort study demonstrates that 9-valent HPV vaccination in males aged 9-26 years is associated with a 46% reduction in HPV-related cancer risk. The findings support sex-neutral HPV vaccination strategies and highApr 15, 2026One Dose of HPV Vaccine Noninferior to Two: Implications for Global Cervical Cancer PreventionA randomized trial of 20,330 girls 12–16 years shows one dose of bivalent or nonavalent HPV vaccine prevents persistent HPV16/18 infection as effectively as two doses over 5 years, with high effectiveness and no safety signals.Dec 3, 2025Immunogenicity and HPV Infection After One, Two, and Three Doses of Quadrivalent HPV Vaccine in Indian Girls: A Multicentre Prospective Cohort StudyThis study evaluates immune responses and HPV infection rates in Indian girls after receiving one, two, or three doses of the quadrivalent HPV vaccine, supporting WHO’s recommendation for two doses spaced at least six months apart.Nov 24, 2025Recombinant Quadrivalent Influenza Vaccine (RIV4) Shows Non‑Inferior Immunogenicity and Acceptable Safety in 9–17‑Year‑Olds: Results of a Phase 3 Immunobridging Study
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
A phase 3 immunobridging study found that a single dose of recombinant quadrivalent influenza vaccine (RIV4) induced non‑inferior HAI responses in 9–17‑year‑olds vs 18–49‑year‑olds, with a comparable safety profile and fewer solicited react
Nov 23, 2025
Seventeen Years On: Robust Population-Level Effectiveness and Herd Protection from HPV Vaccination in High-Risk Young WomenSeventeen years after HPV vaccine introduction, substantial reductions in vaccine-type HPV prevalence confirm strong effectiveness and herd protection among vaccinated and unvaccinated sexually experienced adolescent girls and young women aOct 6, 2025
Beyond Cervical Cancer: The Rising Threat of HPV-Linked Oropharyngeal Cancer in MenHPV-related oropharyngeal cancer incidence has surpassed cervical cancer, with men facing a 5-10 fold higher risk. Understanding this shift, symptoms, risks, and the critical role of HPV vaccination can transform prevention and early detectOct 7, 2025